Inactive Instrument

Analyst Reco. LogicBio Therapeutics, Inc.

Equities

Chardan Research Cuts Price Target on LogicBio Therapeutics to $2.50 From $4, Reiterates Buy Rating	22-08-22	MT
Chardan Capital Adjusts LogicBio Therapeutics' Price Target to $4 from $6, Keeps Buy Rating	22-05-17	MT
William Blair Upgrades LogicBio Therapeutics to Outperform From Market Perform	22-05-10	MT
William Blair Downgrades LogicBio Therapeutics to Market Perform From Outperform	22-02-03	MT
Chardan Cuts LogicBio Therapeutics' Price Target to $6 From $16 After FDA Places LB-001 Trial on Hold; Buy Rating Kept	22-02-03	MT
Chardan Research Lowers LogicBio Therapeutics' Price Target to $16 From $20, Citing LB-001 Study Timeline; Buy Rating Kept	21-12-23	MT
Barclays Adjusts Price Target on LogicBio Therapeutics to $8 From $24, Reiterates Overweight Rating	21-11-17	MT
LOGICBIO THERAPEUTICS : HC Wainwright Starts LogicBio Therapeutics at Buy With $15 Price Target	21-06-07	MT
LOGICBIO THERAPEUTICS : JMP Securities Starts LogicBio Therapeutics at Market Outperform With $17 Price Target	21-03-04	MT

No results for this search